385 related articles for article (PubMed ID: 16625088)
1. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans.
Abbott JJ; Oliveira AM; Nascimento AG
Am J Surg Pathol; 2006 Apr; 30(4):436-43. PubMed ID: 16625088
[TBL] [Abstract][Full Text] [Related]
2. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.
Mentzel T; Beham A; Katenkamp D; Dei Tos AP; Fletcher CD
Am J Surg Pathol; 1998 May; 22(5):576-87. PubMed ID: 9591728
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution.
Bowne WB; Antonescu CR; Leung DH; Katz SC; Hawkins WG; Woodruff JM; Brennan MF; Lewis JJ
Cancer; 2000 Jun; 88(12):2711-20. PubMed ID: 10870053
[TBL] [Abstract][Full Text] [Related]
4. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up.
Goldblum JR; Reith JD; Weiss SW
Am J Surg Pathol; 2000 Aug; 24(8):1125-30. PubMed ID: 10935653
[TBL] [Abstract][Full Text] [Related]
5. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Hisaoka M; Okamoto S; Morimitsu Y; Tsuji S; Hashimoto H
Virchows Arch; 1998 Oct; 433(4):323-9. PubMed ID: 9808434
[TBL] [Abstract][Full Text] [Related]
6. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans.
Goldblum JR
Arch Pathol Lab Med; 1995 Mar; 119(3):238-41. PubMed ID: 7534057
[TBL] [Abstract][Full Text] [Related]
7. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases.
Szollosi Z; Nemes Z
J Clin Pathol; 2005 Jul; 58(7):751-6. PubMed ID: 15976346
[TBL] [Abstract][Full Text] [Related]
8. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.
Llombart B; Monteagudo C; Sanmartín O; López-Guerrero JA; Serra-Guillén C; Poveda A; Jorda E; Fernandez-Serra A; Pellín A; Guillén C; Llombart-Bosch A
J Am Acad Dermatol; 2011 Sep; 65(3):564-575. PubMed ID: 21570152
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.
Liang CA; Jambusaria-Pahlajani A; Karia PS; Elenitsas R; Zhang PD; Schmults CD
J Am Acad Dermatol; 2014 Oct; 71(4):781-6. PubMed ID: 24755121
[TBL] [Abstract][Full Text] [Related]
10. [Fibrosarcomatous dermatofibrosarcoma protuberans: a clinicopathological analysis of 12 cases].
Zhang J; Wu N; Xia C; Wei X; Shi QL; Zhou XJ; Ma J
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):753-7. PubMed ID: 24447553
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases.
Díaz-Cascajo C; Weyers W; Borrego L; Iñarrea JB; Borghi S
Am J Dermatopathol; 1997 Dec; 19(6):562-7. PubMed ID: 9415611
[TBL] [Abstract][Full Text] [Related]
12. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: prognostic significance of clinicopathologic variables.
Erdem O; Wyatt AJ; Lin E; Wang X; Prieto VG
Am J Dermatopathol; 2012 Feb; 34(1):24-34. PubMed ID: 21785324
[TBL] [Abstract][Full Text] [Related]
15. Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases.
Shah KK; McHugh JB; Folpe AL; Patel RM
Am J Surg Pathol; 2018 Mar; 42(3):413-419. PubMed ID: 29240584
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for distant metastasis of dermatofibrosarcoma protuberans.
Hayakawa K; Matsumoto S; Ae K; Tanizawa T; Gokita T; Funauchi Y; Motoi N
J Orthop Traumatol; 2016 Sep; 17(3):261-6. PubMed ID: 27289468
[TBL] [Abstract][Full Text] [Related]
17. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.
Reimann JD; Fletcher CD
Am J Surg Pathol; 2007 Sep; 31(9):1371-7. PubMed ID: 17721193
[TBL] [Abstract][Full Text] [Related]
18. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: a cohort study.
Hoesly PM; Lowe GC; Lohse CM; Brewer JD; Lehman JS
J Am Acad Dermatol; 2015 Mar; 72(3):419-25. PubMed ID: 25582537
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group.
Terrier-Lacombe MJ; Guillou L; Maire G; Terrier P; Vince DR; de Saint Aubain Somerhausen N; Collin F; Pedeutour F; Coindre JM
Am J Surg Pathol; 2003 Jan; 27(1):27-39. PubMed ID: 12502925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
